Navigation Links
Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
Date:2/12/2008

as filed with the United States Securities and Exchange Commission on February 12, 2008. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Genoptix undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

[Financial tables follow]

GENOPTIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

December 31,

2007 2006

Assets

Current assets:

Cash and cash equivalents $50,624 $3,865

Investment securities available-for-sale 34,836 -

Accounts receivable, net of allowance for

doubtful accounts 9,013 4,766

Other current assets 1,409 270

Total current assets 95,882 8,901

Property and equipment, net 1,950 1,287

Other long-term assets - 14

Total assets $97,832 $10,202

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses $4,312 $1,987

Accrued compensation 2,496 1,058

Deferred revenue 95 39

Current portion of long-term debt - 1,524

Total current liabilities 6,903 4,608

Deferred rent
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
2. Genoptix, Inc. Announces Pricing for Initial Public Offering
3. MIB Life Index Reports North American Life Insurance Activity Up 1.4% in December
4. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
5. Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results
6. Mesa Labs Reports Higher Quarterly Sales and Earnings
7. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
8. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
9. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Neurobiological Technologies Reports Second Quarter Financial Results
11. Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Though the number of jobs created i... companies reported a different kind of slowdown: ...s months. , Seattle, WA (...created in the medical field slowed in June overal...ind of slowdown that will be music to the ears of ...
(Date:7/25/2008)... supporting the US Department of Defense and Feder... Phoenix. Operation Golden Phoenix is a, four-da...ned to assist, federal, state and local agencies w...os. Dataline is providing a vital, ad-hoc, secure ... use during the exercise., NORFOLK, Va., July 25 ...
(Date:7/25/2008)...elationship Based on Significant Improvements in M...MDdatacor, Inc., a leader in health,care quality m..., today,announced it has entered into a long-term ...rt Wellmark,s Collaboration on Quality(SM) Incent ...ion between Wellmark and,primary care clinicians t...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...V and AIDS in India says that women and children a...the most likely one to be withdrawn// from school ...h AIDS. The National AIDS Control Organisation (NA...llion of the 5.2 million HIV/AIDS cases in India i...
... recently been developed by scientists. This appro...many malignancies before// they turn dangerous. Th... they have applied this technique to detect leukem...atic approach to diagnosing cancer at the molecula...
...researchers at the MassGeneral Institute for Neuro...bitor of an enzyme known as Poly //(ADP-ribose) po...untington’s disease affected cells from undergoing...rugs can be developed to treat Huntington's diseas...
...launched an International Stem Cell Research Insti...em cell research. // The academic medical center a...lopmental geneticist Nissim Benvenisty, M.D., Ph.D...g with David I. Meyer, Ph.D., vice president of Re...
Other Medicine News:Health News:New Technique To Diagnose Cancer At Molecular Level 2Health News:Targeting PARP1 Is Effective In Protecting HD Cells from Damage 2Health News:Center Launches New International Stem Cell Research Institute 2
(Date:7/22/2008)...pment Initiative bring MJFF,s,current active indus...,2009, NEW YORK, July 22 /PRNewswire-USNewswire/...ansformative treatments and a cure for Parkinson,s...son,s Research has awarded,$2.7 million in total f...were granted under MJFF,s Therapeutics Development...
(Date:7/22/2008)...acy of Treating Patients with ...GIN-SI, South Korea, July 22 /-,Jenne... and its South,Korean partner Green Cross Corp., a...clinical trial of its first-in-class lead product ...rated and resulted in clear,anti-cancer efficacy i...
(Date:7/22/2008)...dra(R) Resulted in Significant, Reductions in A1C ...orithm Used, BRI...om the "Adjust to,Target in Type 2 Diabetes: Compa...ng for Adjustment of Mealtime Insulin Glulisine" s...ciation,s (ADA) medical journal,Diabetes Care. Th...
(Date:7/22/2008)...RNewswire/ -- Hyperion,Therapeutics, Inc. today an...n its Phase 1/2 clinical trial to evaluate the saf...f HPN-100 (formally called GT4P) versus,BUPHENYL(R...cle disorders,(UCD). The company plans to announce...ar., (Logo: http://www.newscom.com/cgi-bin/prnh/...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 1GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 2GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 3St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 1St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 1Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 3Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 4Pharmaxis to Apply to Market Bronchitol in Australia 3283 1Pharmaxis to Apply to Market Bronchitol in Australia 3283 2Pharmaxis to Apply to Market Bronchitol in Australia 3283 3
...n three investigational,agents (VEGF Trap, S-1 and...SCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNe...y that a total of 375 abstracts,indicative of its ...d Annual Meeting of the American Society of Clinic... 2007). The results from key,studies involving the...
...INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today...of INNO-406, an orally bioavailable dual Bcr-Abl a...r,treatment-intolerant chronic myelogenous leukemi...of Clinical Oncology Annual,Meeting. The meeting t...hicago, Illinois., Information related to the pres...
Other Medicine Technology:Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: